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Abstract
Background: Virtually all prostate cancer deaths occur due to obtaining the castration-resistant phenotype after
prostate cancer cells escaped from apoptosis and/or growth suppression initially induced by androgen receptor
blockade. TNF-related apoptosis-inducing ligand (TRAIL) was an attractive cancer therapeutic agent due to its minimal
toxicity to normal cells and remarkable apoptotic activity in tumor cells. However, most localized cancers including
prostate cancer are resistant to TRAIL-induced apoptosis, thereby creating a therapeutic challenge of inducing TRAIL
sensitivity in cancer cells. Herein the effects of cyproterone acetate, an antiandrogen steroid, on the TRAIL-induced
apoptosis of androgen receptor-negative prostate cancer cells are reported.
Methods: Cell apoptosis was assessed by both annexin V/propidium iodide labeling and poly (ADP-ribose) polymerase
cleavage assays. Gene and protein expression changes were determined by quantitative real-time PCR and western
blot assays. The effect of cyproterone acetate on gene promoter activity was determined by luciferase reporter assay.
Results: Cyproterone acetate but not AR antagonist bicalutamide dramatically increased the susceptibility of androgen
receptor-negative human prostate cancer PC-3 and DU145 cells to TRAIL-induced apoptosis but no effects on
immortalized human prostate stromal PS30 cells and human embryonic kidney HEK293 cells. Further investigation of the
TRAIL-induced apoptosis pathway revealed that cyproterone acetate exerted its effect by selectively increasing death
receptor 5 (DR5) mRNA and protein expression. Cyproterone acetate treatment also increased DR5 gene promoter
activity, which could be abolished by mutation of a consensus binding domain of transcription factor CCAAT-
enhancer-binding protein homologous protein (CHOP) in the DR5 gene promoter. Cyproterone acetate increases CHOP
expression in a concentration and time-dependent manner and endoplasmic reticulum stress reducer 4-phenylbutyrate
could block cyproterone acetate-induced CHOP and DR5 up-regulation. More importantly, siRNA silencing of CHOP
significantly reduced cyproterone acetate-induced DR5 up-regulation and TRAIL sensitivity in prostate cancer cells.
Conclusions: Our study shows a novel effect of cyproterone acetate on apoptosis pathways in prostate cancer cells and
raises the possibility that a combination of TRAIL with cyproterone acetate could be a promising strategy for treating
castration-resistant prostate cancer.
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Background
Prostate cancer is the most common non-skin malig-
nancy in males in developed countries, and the second
most frequent cause of male cancer-related death [1].
Androgen deprivation/castration is the principal option
for treating prostate cancer. Cyproterone acetate (CPA),
a synthetic steroid was initially utilized for prostate can-
cer treatment because of its ability to block the androgen
receptor (AR) and reduce serum testosterone levels.
CPA has shown favorable results when used as androgen
deprivation monotherapy for advanced prostate cancer
[2] and continues to be a drug of interest to oncologists
treating prostate cancer [3]. However, CPA also binds to
a range of other steroid receptors [4]. Patients in the US
with locally advanced prostate cancer typically receive
gonadotropin-releasing hormone inhibitors and/or a
nonsteroidal pure anti-androgen such as bicalutamide
(Bic) for obtaining maximal androgen blockade with
minimal off-target effects. Unfortunately, prostate cancer
eventually becomes castration resistant (CR) and prolif-
erates despite continued androgen deprivation therapy
[5–7]. A major challenge in the field of prostate cancer
research is to develop more efficacious treatments for
CR prostate cancer.
Dysregulation of apoptosis in cancer contributes to
uncontrolled cell growth and is a hallmark of malig-
nancy. Consequently, reactivating and/or triggering
apoptosis in cancer cells is a frequent goal of new anti-
cancer therapies. TRAIL is a promising cancer thera-
peutic agent due to its minimal toxicity to normal cells
and remarkable apoptotic activity in cancer cells [8–10].
Upon binding to its death receptor 5 (DR5), TRAIL in-
duces the formation of the Death Inducing Signaling
Complex (DISC) that includes DR5, the adaptor mol-
ecule FADD and pro-caspase-8. This causes the activa-
tion of caspase-8, leading to the activation of caspase-9
and subsequently activation of the executioner caspases
(caspase-3, −6 and −7) [11–13]. These latter caspases
degrade substrates such as poly (ADP-ribose) polymer-
ase (PARP) to cause apoptosis. Several phase II clinical
cancer therapy trials were conducted in which either
recombinant TRAIL or monoclonal antibodies that have
a longer half-life and selectively activate DR5 were
administered to patients with cancers expected to re-
spond to this therapy. These drugs were well toler-
ated but their benefits were modest and typically did
not achieve statistical significance of efficacy [14–17],
leading to a generalized conclusion that primary can-
cers are TRAIL-resistant.
Similar to localized in situ tumors, various prostate
cancer cell lines are also resistant to TRAIL-induced
apoptosis [18]. During the course of preliminary experi-
ments with prostate cancer cell lines PC-3 and DU145,
we serendipitously noted an unexpected finding that the
sensitivity of these androgen-independent cells to TRAIL
was markedly enhanced when the cells had been pre-
treated with CPA. Our further study demonstrated that
CPA enhances TRAIL-induced apoptosis in AR-negative,
androgen-independent prostate cancer cells by up-
regulation of DR5. This up-regulation occurs after induc-
tion of transcription factor CCAAT-enhancer-binding
protein homologous protein (CHOP) protein, which then
binds to the promoter of the DR5 gene to increase its ex-
pression. To the best of our knowledge, our results are the
first to show this effect of CPA on TRAIL-induced pros-
tate cancer cell apoptosis, and raise the possibility that a
combination of TRAIL with CPA for its associated efficacy
unrelated to androgen antagonism could improve treat-
ment of CR prostate cancer.
Methods
Cell lines and culture
DU145 (ATCC® HTB-81™), PC-3 (ATCC® CRL-1435™)
and HEK293 (ATCC® CRL-1573™) cell lines were from
the American Type Culture Collection (Manassas, VA).
Immortalized human prostate stromal PS30 cells were
kindly provided by Dr. Debra Schwinn (Duke University
Medical Center) [19]. DU145 and HEK293 cells were
cultured in DMEM medium with 10% fetal bovine
serum (FBS); PC-3 and PS30 cells were cultured in
RPMI 1640 medium with 10% FBS. Before treatment
with compounds, FBS in culture medium was reduced
to 2%. CPA, Bic, cycloheximide and 4-phenylbutyrate
(4-PBA) were purchased from Sigma-Aldrich (St. Louis,
MO). Recombinant TRAIL was a gift from Dr. Xu Luo
(University of Nebraska Medical Center) [20].
Apoptosis assay
The ApopNexin™ FITC Apoptosis Detection Kit (Millipore,
Billerica, MA) was used for the annexin V/propidium iod-
ide (PI) flow cytometry analysis of early apoptosis by FACS-
Caliber cytometry (BD Biosciences) at the Creighton
University Flow Cytometry Core Facility. PARP antibody
(#9532, Cell Signaling Technology, Beverly, MA) was used
to detect cleavage of PARP for the western blot method of
apoptosis detection. The percentage of cleaved PARP
(89 kDa) in total PARP (116 kDa full length plus cleaved
PARP) was used as indicator of apoptosis.
Western blot assay
Protein extracts from cultured cells were quantified
using Pierce™ Coomassie (Bradford) Protein Assay Kit
(Thermo Fisher Scientific, Waltham, MA) and then
subjected to western blot analysis as we reported [21].
Primary antibodies against DR5 (#AB16942, Milllipore),
caspase-8 (#9746, Cell Signaling Technology), FLIP
(#3210, Cell Signaling Technology), FADD (#610399, BD
Transduction Laboratories™), CHOP (#2895, Cell Signaling
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Technology), β-actin (Santa Cruz Biotechnology) and Bid
(kindly provided by Dr. Xu Luo) [20] were used to detect
relevant proteins of interest.
Quantitative real-time PCR
Total RNA extraction and quantitative real-time PCR
were conducted as described [22]. The DR5, DR4 and
β-actin primers are listed in Additional file 1: Table S1.
Construction of plasmids
All primers are shown in Additional file 1: Table S1. The
DR5 promoter fragments (−711/+3) were amplified from
DU145 cell genomic DNA by PCR with BglII- and
HindIII-flanked primers and cloned into the pGL3-Basic
luciferase reporter vector (Promega, Fitchburg, WI).
Progressive deletion mutants of the DR5 promoter were
created by PCR with promoter-specific primers, using
the DR5 promoter luciferase plasmid (−711/+3) as a
template. The DR5 luciferase plasmid DR5-P(mtCHOP)
with mutations in the CHOP binding site was generated
by over-lap PCR. Nucleotide changes are underlined. All
constructs were validated by DNA sequencing.
Plasmids transfection and luciferase reporter assay
DU145 cells (1.6 × 105 cells) were co-transfected with
100 ng of the Renilla luciferase plasmid pRL-SV40P
(Addgene) and 400 ng of firefly luciferase constructs
containing the DR5 promoter region using Lipofecta-
mine 2000 (Life Technologies). After 24 h, the cells were
treated with CPA or solvent for an additional 24 h. A
Dual-Glo® Luciferase Assay kit (Promega) and Sirius lu-
ciferase assay system (Berthold, Germany) were used to
detect luciferase activity and the firefly luciferase activity
was normalized by Renilla luciferase activity.
Small interference RNA (siRNA) transfection
CHOP siRNA (#L-004819-00-0005) and control siRNA
(#D-001810-01-05) were purchased from GE Dharmacon
(Lafayette, CO). DU145 cells were transfected with 300
nM siRNA using Nucleofector® II Device (Lonza,
Walkersville, MD) according to manufacturer’s in-
structions. 24 h later, cells were subjected to treat-
ment with the indicated compounds.
Data statistical analysis
Data are expressed as means ± SEM of at least three de-
terminations. Groups were compared using Student’s t
test for unpaired observations or two-way ANOVA
with the Bonferroni correction for multiple compari-
sons. * p < 0.05; ** p < 0.01; ns, not significant.
Results
CPA enhances TRAIL-induced apoptosis in androgen-
independent prostate cancer cells
PC-3 and DU145 are two androgen-independent pros-
tate cancer cell lines and also often characterized as AR
negative. We first examined the effect of CPA treatment
on TRAIL-induced apoptosis in these two cell lines.
Using the annexin V/PI assay method, we found that
CPA (50 μM) alone only slightly increased apoptosis of
PC-3 cells in the absence of TRAIL, while significantly
enhanced TRAIL-induced cell apoptosis by 2.5-fold
(Fig. 1a). Western blot analysis of PARP cleavage con-
firmed that CPA treatment not only increased the max-
imum PARP cleavage by 3-fold but also reduced the
TRAIL concentration needed to induce 50% of maximal
cleavage of PARP (the EC50) from 50 ng/ml to 20 ng/ml
(Fig. 1b). DU145 cells are highly resistant to TRAIL-
induced apoptosis with only a marginal increase in
PARP cleavage observed even in the presence of 100 ng/
ml TRAIL. Pretreatment of CPA (50 μM) sensitized
DU145 cells to TRAIL-induced apoptosis (Fig. 1c). At
100 ng/ml TRAIL, PARP cleavage was increased from 5
to 40% by CPA pretreatment.
However, another classical AR antagonist Bic
(50 μM) had no effects on TRAIL induced cleavage
of PARP in PC-3 and DU145 cells (Fig. 1d). As ex-
pected, immortalized normal human prostate stromal
PS30 cells are resistant to TRAIL. Pretreatment with
50 μM CPA had no significant effects on TRAIL
(50 ng/ml) induced cleavage of PARP in these pros-
tate cells whereas cleavage of PARP in DU-145 cells
were increased by 4-fold (Fig. 1e). Therefore, we fo-
cused our studies on DU145 cells.
Effects of CPA on TRAIL-induced apoptosis are dependent
on the activation of caspase-8
The binding of TRAIL to its DR5 receptor leads to the
cleavage and activation of caspase-8, a critical step in the
extrinsic pathway for cell apoptosis. As shown in Fig. 2a,
CPA enhanced TRAIL-induced production of the p18
fragment of caspase-8 in DU145 cells and markedly
increased TRAIL-induced cleavage of the BH3-only
protein Bid, a critical mediator of the mitochondrial
apoptotic pathway. Pretreatment with caspase-8 inhibi-
tor Z-IETD-FMK effectively blocked CPA/TRAIL-
induced caspase-8 p18 production by over 90% (Fig. 2b).
Importantly, CPA-enhanced TRAIL-induced cleavage of
Bid (Fig. 2c) and PARP (Fig. 2d) was also blocked by
Z-IETD-FMK pretreatment.
CPA selectively up-regulates DR5 expression in prostate
cancer cells
We next examined the components of the DISC and its
negative regulator FLIP [23] in DU145 cells for illustrating
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the potential regulation by CPA. While FLIP and
other DISC components (caspase-8 and FADD) did
not show a change, DR5 protein was elevated follow-
ing CPA treatment in a time- and concentration-
dependent manner (Fig. 3a, b).
We further determined if the elevated DR5 protein
level seen with CPA treatment was due to a pro-
longed DR5 protein half-life. DU145 cells without or
with CPA-induced DR5 elevation were incubated with
cycloheximide to block new protein biosynthesis. The
disappearance of DR5 was followed over time by
western blot. Figure 3c shows a representative west-
ern blot indicating that independent of CPA treat-
ment, DR5 was gradually degraded with a half-life of
at least 8 h and CPA treatment had no significant
effects on DR5 degradation.
Fig. 1 CPA sensitized AR-negative androgen-independent prostate cancer cells to TRAIL-induced apoptosis. a PC-3 cells were pretreated without
(control) or with 50 μM CPA for 24 h, and then treated without or with 50 ng/ml TRAIL for 6 h. Both suspended and attached cells were harvested.
Apoptosis was measured by the annexin V/PI flow cytometry method as described in Materials and Methods. Left panel, representative flow cytometry
histograms of apoptosis assay; right panel, statistical analysis of results from three independent experiments. Data are means ± S.E. with **p < 0.01. PC-3
cells b and DU145 cells c were pretreated without or with 50 μM CPA for 24 h, and then treated with indicated concentrations of TRAIL for 6 h. d PC-3
and DU145 cells were pretreated without (control) or with 50 μM Bic for 24 h, and then treated without or with 50 ng/ml TRAIL for 6 h. e PS30 and
DU145 cells were pretreated without or with 50 μM CPA for 24 h, and then treated without or with 50 ng/ml TRAIL for 6 h. Cleavage of PARP was
measured by western blot analysis. Data shown are means ± S.E. (n = 3) with **p < 0.01, ns: not significant. Insets: Representative western blot images
of PARP and β-actin
Chen et al. BMC Cancer  (2017) 17:179 Page 4 of 11
We also carried out quantitative RT-PCR analysis to
investigate DR5 mRNA changes induced by CPA
treatment. As shown in Fig. 3d, CPA increased DR5
mRNA expression by approximately 2-fold at 6 h and
this induction was persistent over the ensuing 24 h.
In addition, CPA increased DR5 mRNA levels, but
not DR4 mRNA levels, in a concentration-dependent
manner (Fig. 3e).
CPA stimulates DR5 promoter activity via a CHOP binding
motif in prostate cancer cells
DR5 proximal promoter containing a 714-bp DNA frag-
ment upstream of the human DR5 coding region was
amplified using the genomic DNA from DU145 cells as
a template, cloned into the luciferase reporter vector
pGL3-Basic, and designated as DR5-P(−711/+3) (the
“+3” represents the third base from the putative tran-
scription start site). Luciferase reporter gene constructs
containing the various 5’ flanking regions of the DR5
promoter were also generated (Fig. 4a, upper section).
The constructs were transiently transfected into DU145
cells, and their promoter activities were determined in
the presence or absence of 50 μM CPA. As shown in
Fig. 4a (lower section), following deletion, the DR5-
P(−552/+3) plasmid still retains the basal promoter ac-
tivity, similar to that of the DR5-P(−711/+3) plasmid.
CPA treatment increased the promoter activities of
DR5-P(−711/+3) and DR5-P(−552/+3) by 1.9- and 2.2-
fold, respectively. The DR5-P(−294/+3) plasmid still
retains 62% of the DR5-P(−711/+3) basal promoter
activity and displayed a similar CPA induction of DR5-
P(−711/+3) (1.61- versus 1.9-fold). However, a further 96-
bp deletion of DR5-P(−294/+3) resulted in a significant
loss of the basal promoter activity (0.34 versus 0.62) and
the complete loss of CPA induction, suggesting that this
deleted 96-bp fragment (−294/−198) contains key ele-
ments of the DR5 promoter that may be responsible for
the stimulatory effect of CPA.
Using TFSEARCH, a tool for locating transcription factor
binding sites, we identified a consensus transcription factor
CHOP binding domain at −276/-264 bp in this 96-bp
fragment (Fig. 4b, upper panel). CHOP is reported to be
responsible for DR5 up-regulation induced by many drugs
[24]. To determine whether the CHOP-binding motif is
critical for CPA-stimulated DR5 promoter activity, we
mutated the consensus CHOP-binding domain in DR5-
P(−552/+3) plasmid. Mutation of this consensus CHOP
binding domain significantly reduced the basal promoter
activity by 50% and completely abolished CPA induction
(Fig. 4b, lower panel). These results demonstrate that this
consensus CHOP binding domain (−276/−264) is critical
for both basal and CPA-activated DR5 promoter activity.
Endoplasmic reticulum stress (ER stress) is involved in CPA
induced CHOP protein up-regulation in prostate cancer cells
We next examined whether CPA increased CHOP pro-
tein expression in prostate cancer cells. The basal level
of CHOP protein is very low in DU145 cells, but was
Fig. 2 Effects of CPA on TRAIL-induced apoptosis are dependent on the activation of caspase-8. DU145 cells were pretreated without or with 50 μM
CPA for 24 h, and then treated without or with 50 ng/ml TRAIL for 6 h. When needed, 10 μM Z-IETD-FMK was pre-added to cells 1 h before TRAIL
treatment. Cells were harvested and subjected to western blot analysis. a Representative western blot images of PARP, caspase-8 p18, Bid and β-actin
were shown. The western blot results were quantitated and normalized to β-actin. The caspase-8 p18 b and Bid c protein levels relative to those of
control cells and the percentage of cleaved PARP d are shown. Data shown are means ± S.E. (n = 3) with **p < 0.01
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significantly increased following 6 h treatment with
various concentrations of CPA (Fig. 5a). CPA (50 μM)
treatment increased CHOP protein expression in a time-
dependent manner to a maximal 6-fold induction at the
time of 6 h and this induction was gradually reduced but
was still 2-fold higher than the basal level at the time of
30 h (Fig. 5b). Since CHOP protein is a marker of ER
stress [25], we also investigated whether CPA induced
CHOP protein could be blocked by ER stress reducer
4-phenylbutyrate (4-PBA). As shown in Figs. 5c, d, after
pretreatment of DU145 cells with 5 mM 4-PBA, CPA
induced up-regulation of CHOP and DR5 protein were
reduced by 40–50%. Furthermore, we found that neither
DR5 protein expression nor TRAIL induced cleavage of
PARP was affected by CPA treatment in ER stress resist-
ant HEK293 cells (Additional file 2: Figure S1).
Up-regulated CHOP contributes to CPA-induced DR5 up-
regulation and TRAIL sensitivity in prostate cancer cells
To further determine whether CHOP is responsible for
CPA-enhanced DR5 protein expression, DU145 cells
were transfected with control siRNA or CHOP-specific
Fig. 3 CPA selectively up-regulates DR5 expression in prostate cancer cells. DU145 cells were treated with 50 μM CPA for the indicated time a or
indicated concentrations of CPA for 12 h b. Cells were harvested and subjected to western blot analysis. Data shown are means ± S.E. (n = 3) with
**p < 0.01. β-actin was used as a loading control and the indicated protein level in control cells without CPA treatment was normalized as one.
(a, left panel) and (b, inset): Representative western blot images of indicated proteins. c DU145 cells were pretreated without or with 50 μM CPA
for 24 h, and then treated with 50 μM cycloheximide for 10 min (time = 0). Cells were harvested at indicated times and subjected to western blot
analysis. Data shown are means ± S.E. (n > 3) with **p < 0.01. DR5 protein levels at 0 h were set as one. Inset: Representative western blot images
of DR5 and β-actin. d and e DU145 cells were treated with 50 μM CPA for the indicated time d or indicated concentrations of CPA for 6 h e. DR4 and DR5
mRNA levels were determined by quantitative RT-PCR analysis. β-actin was used as an internal control. Data shown are means ± S.E. (n = 3) with *p< 0.05
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Fig. 4 The CHOP binding domain is critical for CPA-activated DR5 gene promoter activity. DU145 cells were transfected with the luciferase reporter
plasmids containing various lengths of the DR5 gene promoter. Cells were treated without or with 50 μM CPA for 24 h and then subjected to
luciferase activity assays. a Upper panel, schematic structure of reporter plasmids; lower panel, statistical analysis of three independent luciferase assay
results. Data shown are means ± S.E. with **p < 0.01, ns: not significant. The relative luciferase activity of DR5-P(−711/+3) without CPA treatment was
set as one. b Upper panel, schematic structure of DR5 promoter reporter plasmids containing wide-type or mutated CHOP binding site; lower panel,
statistical analysis of three independent luciferase assay results. Data shown are means ± S.E. with **p < 0.01, ns: not significant. The relative luciferase
activity of DR5-P(−552/+3) without CPA treatment was set as one
Fig. 5 ER stress is involved in CPA induced CHOP protein up-regulation in prostate cancer cells. DU145 cells were treated with the indicated
concentrations of CPA for 6 h a or 50 μM CPA for the indicated times b. c and d DU145 cells were pretreated with 5 mM ER stress reducer 4-PBA for 1 h,
and then treated with 50 μM CPA for 6 h c or 30 h d. Cells were harvested and subjected to western blot analysis. β-actin was used as a loading control
and the indicated protein level in control cells without treatment was set as one. Data shown are means ± S.E. (n> 3) with * p< 0.05, ** p< 0.01. Insets:
Representative western blot images of CHOP, DR5 and β-actin
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siRNA for 24 h, followed by CPA (50 μM) treatment
for 6 h. As shown in Fig. 6a, CHOP siRNA largely
abolished CPA-induced CHOP expression at the time
of 6 and 30 h. Silencing CHOP expression reduced
CPA-enhanced DR5 protein expression by about
50% (Fig. 6b, c). More importantly, silencing CHOP
expression reduced CPA-stimulated TRAIL-induced
PARP cleavage from 40 to 20% (Fig. 6b, d). An
annexin V/PI flow cytometry analysis indicated that
CPA treatment only increased TRAIL induced cell
apoptosis by 1.3-fold in CHOP-silenced DU145 cells
as compared 2-fold in control DU145 cells (Fig. 6e).
Together, our results suggest that induction of CHOP
plays an important role in CPA-enhanced TRAIL-
induced prostate cancer cell apoptosis.
Discussion
TRAIL/DR activation triggers the external apoptosis
pathway, which is proposed to be effective against tumors
that have acquired resistance to conventional therapy
[8, 15, 17]. However, prostate cancer is comparatively
resistant to TRAIL-treatment as confirmed in our
preliminary studies with prostate cancer cell lines
DU145 and PC-3. Thus, the focus has shifted toward
developing compounds and/or combination therapies
that improve cancer cell susceptibility to TRAIL in a
clinical setting [26]. A few small molecule inhibitors
or natural compounds were found to enhance the
efficacy of TRAIL-induced apoptosis of prostate can-
cer cells [27]; nevertheless, their mechanism of action
and toxicity are typically unknown. To our surprise,
Fig. 6 CHOP up-regulation contributes to CPA induced DR5 up-regulation and TRAIL sensitivity in prostate cancer cells. a DU145 cells were transfected
with control siRNA or CHOP siRNA for 24 h, and then treated without or with 50 μM CPA for 6 and 30 h. Cells were then harvested and subjected
to western blot analysis. A representative western blot result for the indicated proteins of three separate experiments is shown. b-e DU145 cells
transfected with control siRNA or CHOP siRNA were treated without or with 50 μM CPA for 24 h, followed by 6 h of treatment without or with 50 ng/
ml TRAIL. Cells were then harvested and subjected to western blot analysis. A representative western blot result for the indicated proteins is shown in
b. The relative DR5 protein level and cleavage of PARP were quantitated and are shown in c and d, respectively. β-actin was used as a loading control.
Data shown are means ± S.E. (n > 3) with **p < 0.01. (E) Apoptosis was measured by the annexin V/PI flow cytometry method. Left panel, representative
flow cytometry histograms of apoptosis assay; right panel, statistical analysis of results from three independent experiments. Data are means ± S.E.
with *p < 0.05
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we noted that pretreatment of AR-negative, androgen-
independent prostate cancer PC-3 and DU145 cells
with anti-androgen CPA greatly enhanced their sensi-
tivity to TRAIL.
TRAIL typically activates the extrinsic apoptosis
pathway by binding to death receptors. Upon binding to
its DR5 receptor, TRAIL induces the activation of
caspase-8 that can directly activates caspase-3 via cleav-
age (extrinsic pathway). In most cancer cells, a limited
amount of activated caspase-8 is produced, which is
insufficient to directly cleave and activate caspase-3 [28, 29].
Instead, activated caspase-8 may preferentially cleave the
cytosolic protein Bid [30], causing release of cytochrome c
from mitochondria and the formation of the apoptosome to
activate caspase-3 (intrinsic pathway). The present study
found that CPA treatment significantly increased TRAIL-
induced cleavage of Bid, which was also largely blocked by
the pretreatment with caspase-8 inhibitor Z-IETD-FMK.
This result is consistent with our recent report that Bid is
primarily cleaved by caspase 8 upon TRAIL treatment,
which in turn activates the mitochondrial apoptotic path-
way, leading to degradation of PARP to cause apoptosis [20].
Thus, CPA could enhance TRAIL-induced cell apop-
tosis via intrinsic signaling pathways.
Results of further studies show that this enhanced sen-
sitivity to TRAIL is a consequence of DR5 up-regulation,
which occurred because CPA induces CHOP protein ex-
pression. CHOP protein is a recognized marker of ER
stress [25], and the unfolded protein response induced
by ER stress is a target of many anticancer drugs in de-
velopment [31]. ER stress inducer tunicamycin enhances
TRAIL induced apoptosis in prostate cancer cells [32].
We found that ER stress reducer 4-PBA significantly
attenuates the CPA-induced increases in CHOP and
DR5 expression. In addition, CPA treatment had no
effects on DR5 expression or TRAIL sensitivity in
human embryonic kidney HEK293 cells. Interestingly,
HEK293 cells were shown to be comparatively resist-
ant to ER stress [24]. Thus, our available data suggest
that ER stress is necessary for the CPA enhancement
of TRAIL sensitivity in prostate cancer cells.
CPA represents the first generation of AR blockers
for prostate cancer androgen deprivation therapy.
Since PC-3 and DU145 cells are AR negative and
androgen-independent and a classical AR antagonist
Bic had no effects on TRAIL induced cleavage of
PARP, it is unlikely that CPA enhances TRAIL sensi-
tivity in PC-3 and DU145 cells via its anti-androgen
effects. Interestingly, PC-3 and DU145 cells express
functional glucocorticoid receptors (GR) [33] and a
recent study showed that GR could substitute for AR
function and contributes to CR in prostate cancer
[34]. In fact, GR could confer apoptotic resistance to
chemotherapy in some solid tumors [35]. Inasmuch
as CPA also functions as a GR antagonist [4], this
could be contributing to our observed CPA-enhancement
of TRAIL-induced apoptosis. We are currently investigat-
ing this possibility.
The desire for more robust pure anti-androgens has
driven new drug developments for advanced prostate
cancer over the past many years. Nonetheless, a drug
with multiple targets can sometimes be more effective
than a pure drug [36]. Our data with synthetic steroid
CPA indicate that the inclusion of some off-target effect
Fig. 7 Schematic diagram of the mechanism for CPA enhancement of TRAIL induced apoptosis in prostate cancer cells. CPA treatment induces
CHOP protein expression via ER stress response pathways. CHOP protein binds to the promoter region of DR5 gene and up-regulates DR5 mRNA
and protein expression. Up-regulated DR5 protein arguments TRAIL induced Bid-dependent apoptotic pathways in prostate cancer cells
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of this drug could potentially improve the efficacy of CR
prostate cancer treatment. In contrast to a wide range of
other drugs that have been shown to enhance TRAIL
sensitivity, CPA is approved for clinical use and still re-
mains widely used in many countries. Finding new tricks
for an old drug such as CPA and related off-patent drugs
may represent an efficient pathway for drugs that can be
used in combination with TRAIL therapy to better treat
CR prostate cancer [37]. The appeal of TRAIL as an
anti-cancer agent is due to its selectivity for inducing
apoptosis in cancerous tissue. Our data show that CPA
treatment did not augment TRAIL effects in normal
human prostate stromal cells and embryonic kidney
cells, which suggest that a combination of CPA with
TRAIL is a potential therapeutic strategy without severe
side effects in treating prostate cancer patients.
It should be noted that CPA itself was reported to
have a dose-related hepatotoxicity [2], so regular hepatic
function tests may still be necessary for the patients with
a combination of CPA with TRAIL therapy. Intermittent
treatment with CPA for locally advanced and metastatic
prostate cancer was reported to maintain efficacy while
toxicity and costs were reduced [38]. Given our data, it
seems plausible that adding TRAIL to CPA therapy
could also help curtail the dose-related toxicity. Thus,
further characterization of the precise mechanisms by
which CPA induces susceptibility to TRAIL-mediated
apoptosis may aid with the development of agents
possessing greater long-term efficacy for the treatment
of CR prostate cancer.
Conclusions
Our study demonstrated for the first time that CPA
enhances TRAIL-induced apoptosis in AR-negative,
androgen-independent prostate cancer cells via DR5
up-regulation. Moreover, we found that ER stress-
dependent induction of transcription factor CHOP
contributes to this DR5 up-regulation and apoptosis-
enhanced effect (Fig. 7). Our results therefore raise the
possibility that a combination of TRAIL with CPA for its
associated efficacy unrelated to androgen antagonism
could be a promising strategy for improving treatment
of CR prostate cancer.
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